

CURRICULUM VITAE

Prof. Dr. med. Uwe Platzbecker



Director

Medical Clinic and Policlinic I
Hematology and Cell Therapy
University Hospital Leipzig
Liebigstr. 22
04103 Leipzig, Germany
Email: uwe.platzbecker@medizin.uni-leipzig.de

Education and training

INSTITUTION	DEGREE / CERTIFICATE	YEAR	FIELD OF STUDY / DISCIPLINE
University Hospital "Carl Gustav Carus" at the TU Dresden	Final degree in Medicine ("Staatsexamen")	1996	Medicine
University Hospital "Carl Gustav Carus" at the TU Dresden	MD	1997	Medicine
Fred Hutchinson Cancer Research Center, Seattle	Postdoctoral	2002	Medicine / translational research
University Hospital "Carl Gustav Carus" at the TU Dresden	Board certification	2005	Internal Medicine
University Hospital "Carl Gustav Carus" at the TU Dresden	Board certification	2007	Hematology / Oncology
University Hospital "Carl Gustav Carus" at the TU Dresden	Board certification	2008	Palliative Medicine
University Hospital "Carl Gustav Carus" at the TU Dresden	Board certification	2008	Hemostaseology

Positions and honors

Positions and Employment

Since Oct 2018	Director of the Medical Clinic I, Hematology and Cell Therapy at the University Hospital in Leipzig
2015-Sept 2018	Transcampus Professor of Hematology at the Faculty of Life Science and Medicine at King's College London (UK)
2014-2018	Head of the section of hematology, Dept. of Internal Medicine I, University Hospital "Carl Gustav Carus" at the TU Dresden
2012-2018	Appointment as Professor of Translational Hematology (W2), TU Dresden
2006	Habilitation (Privatdozent)
2005-2012	Senior physician and Head of Hematology out-patient department, Dept. of internal Medicine I, University Hospital "Carl Gustav Carus" at the TU Dresden
2002-2005	Dept. of internal Medicine I, University Hospital "Carl Gustav Carus", at the TU Dresden
2001-2002	Postdoc supported by the Humboldt-Foundation (Feodor Lynen Project) at the Fred Hutchinson Cancer Research Center, Prof. Dr. Deeg, Seattle, USA
1998-2001	Dept. of internal Medicine I, University Hospital "Carl Gustav Carus" at the TU Dresden
1998	Medical practice for Radiology, Grosche/Hupke/Lautenbach, Dresden
1996-1998	Heart Center Dresden, Clinic for Cardio-and Thoracic Vascular Surgery, TU Dresden

Other Experience and Professional Memberships

Professional appointments:

Since 2016	Member of the MDS Foundation's Medical & Scientific Advisory Board
2014-2018	Chair medical ethics committee of the TU Dresden
Since 2013	Chairman of the European Myelodysplastic Syndromes Cooperative Group (EMSCO) by the ELN
Since 2012	Co-Chairman MDS EHA SWG (Chair: P. Fenaux)

Memberships:

Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)
American Society of Hematology (ASH)
European Haematology Association (EHA)
Study Alliance Leukemia (SAL)
Deutsch-Österreichisch-Schweizerische MDS Studiengruppe (DACH)
European Leukemia Net (ELN)
Gesellschaft für Thrombose und Hämostaseologie (GTH)

Honors

2014	EHA educational presentation
2013	ASH educational presentation
2012	Poster award, DGHO
2010	Best Abstract, European Leukemia Net meeting
2009	Poster award, 10 th International Symposium on MDS
2006	Travel award, American Society of Hematology (ASH)
2006	Chugai Science Award

Publications

1. Key figures:

> 250 Publications

Hirsch factor: 37

2. Complete list of published work:

<http://www.ncbi.nlm.nih.gov/pubmed/?term=platzbecker+U>

3. Selected publications

Platzbecker U et al. Measurable-residual disease guided treatment with azacitidine to prevent haematological relapse in patients with MDS and AML – results from the multicenter phase 2 RELAZA2 trial. *Lancet Oncol.* 2018, in press.

Platzbecker U et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. *Lancet Oncol.* 2017 Oct;18(10):1338-1347.

Platzbecker U et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. *Lancet Haematol.* 2015 Oct;2(10):e417-26

Lo-Coco F, et al..., **Platzbecker U**. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med.* 2013 Jul 11;369(2):111-21.

Platzbecker U et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. *J Clin Oncol.* 2017 Feb 20;35(6):605-612.

Platzbecker U et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. *Leukemia.* 2012 Mar;26(3):381-9.